Retatrutide
Price range: $80.00 through $290.00
| Quantity | 5mg*10 vials, 10mg*10 vials, 15mg*10 vials, 20mg*10 vials, 30mg*10 vials, 40mg*10 vials, 60mg*10 vials |
|---|
What to know about retatrutide: Buy Retatrutide Online
1. What is retatrutide?
Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Buy Retatrutide Online
In clinical trials, retatrutide is taken as a once-weekly subcutaneous injection.
2. Where can you get retatrutide?
Retatrutide is not yet available for public use. Lilly is currently studying retatrutide in Phase 3 clinical trials for obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.
3. Is it safe to take retatrutide?
Retatrutide is an investigational molecule that is legally available only to participants in Lilly’s clinical trials, and Lilly is currently evaluating its safety and efficacy in these clinical studies. It has not been reviewed or approved by any regulatory agency, and no one should consider taking anything claiming to be retatrutide outside of a Lilly-sponsored clinical trial. Lilly continues to warn the public about the potential dangers of fake medicines.
4. When was data on retatrutide and obesity with knee osteoarthritis announced?
Phase 2 trial results for retatrutide were presented at the 2023 American Diabetes Association’s (ADA) annual meeting and were published in the New England Journal of Medicine.¹ TRIUMPH-4 (Phase 3) topline results were released in December 2025.²
5. When was data on retatrutide and type 2 diabetes announced?
Lilly announced Phase 3 topline results for retatrutide in adults with type 2 diabetes in March 2026.³
6. What is a GLP-3?
The term “GLP-3” is a scientifically inaccurate label used informally in the media to describe triple hormone receptor agonists, such as Lilly’s retatrutide. This nickname emerged because the medication simultaneously targets three receptors, GLP-1, GIP, and glucagon, rather than representing an actual scientific classification.
A more suitable term to describe retatrutide is “triple agonist,” because it accurately reflects the mechanism of action.
7. What company is developing retatrutide?
Lilly is developing retatrutide.
8. Is retatrutide approved by the FDA?
No. Retatrutide is not currently approved by the FDA and is considered an investigational medication. Lilly is currently evaluating its safety and efficacy in clinical trials.
9. When will retatrutide be available to the public?
Retatrutide is currently in Phase 3 clinical trials, and launch will depend on the completion of these trials and the regulatory approval process. Additional results from the retatrutide clinical trial program are expected over the next year.
10. Which phase is retatrutide in?
Retatrutide has successfully completed two Phase 3 clinical trials:
- TRIUMPH-4 in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity.²
- TRANSCEND-T2D-1 in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.³
Additional trials in the TRIUMPH and TRANSCEND program are underway to evaluate retatrutide’s efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic lower back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.
References:
- Eli Lilly & Company. (June 26, 2023). Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight. PR Newswire. https://www.prnewswire.com/news-releases/lillys-phase-2-retatrutide-results-published-in-the-new-england-journal-of-medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-and-overweight-301863690.html
- Eli Lilly & Company. (December 11, 2025). Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. PR Newswire. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs-along-with-substantial-relief-from-osteoarthritis-pain-in-first-successful-phase-3-trial-302638804.html
- Eli Lilly & Company. (March 19, 2026). Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. PR Newswire. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
Shipping & Delivery
At Ella Peptides Sciences, we process all orders within 1–2 business days after payment confirmation to ensure fast and efficient delivery. Once shipped, you will receive a tracking number via email to monitor your order in real time. We offer reliable USA shipping (3–7 business days) and international delivery (5–10 business days), depending on your location. All orders are carefully packed using secure, discreet packaging to protect product integrity during transit.
Please note that international shipments may be subject to customs duties or taxes, which are the responsibility of the customer. While we strive for timely delivery, delays may occasionally occur due to shipping carriers or customs processing. It is the buyer’s responsibility to ensure products can be legally imported into their country. If you experience any issues or delays, our customer support team is always available to assist you promptly.
Reviews
There are no reviews yet.